These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37272350)

  • 1. Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world.
    Dsilva L; McCarthy K; Lyons J; Cabigas B; Campbell N; Kong G; Adams B; Kuhelj R; Singhal P; Smirnakis K
    Expert Opin Drug Saf; 2023; 22(10):995-1002. PubMed ID: 37272350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
    Ryerson LZ; Foley J; Chang I; Kister I; Cutter G; Metzger RR; Goldberg JD; Li X; Riddle E; Smirnakis K; Kasliwal R; Ren Z; Hotermans C; Ho PR; Campbell N
    Neurology; 2019 Oct; 93(15):e1452-e1462. PubMed ID: 31515290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
    Ryerson LZ; Naismith RT; Krupp LB; Charvet LE; Liao S; Fisher E; de Moor C; Williams JR; Campbell N
    Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing.
    Foley JF; Goelz S; Hoyt T; Christensen A; Metzger RR
    Mult Scler Relat Disord; 2019 Jun; 31():65-71. PubMed ID: 30939392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of natalizumab extended interval dosing.
    Yamout BI; Sahraian MA; Ayoubi NE; Tamim H; Nicolas J; Khoury SJ; Zeineddine MM
    Mult Scler Relat Disord; 2018 Aug; 24():113-116. PubMed ID: 29982107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended interval dosing of natalizumab in multiple sclerosis.
    Zhovtis Ryerson L; Frohman TC; Foley J; Kister I; Weinstock-Guttman B; Tornatore C; Pandey K; Donnelly S; Pawate S; Bomprezzi R; Smith D; Kolb C; Qureshi S; Okuda D; Kalina J; Rimler Z; Green R; Monson N; Hoyt T; Bradshaw M; Fallon J; Chamot E; Bucello M; Beh S; Cutter G; Major E; Herbert J; Frohman EM
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):885-9. PubMed ID: 26917698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons learned after 20 years of real-world experience with natalizumab.
    Khatri BO; Olapo T; Beals S; Lindman E; Perea T; Van Zealand P; Metzger RR
    Mult Scler Relat Disord; 2023 Dec; 80():105048. PubMed ID: 37866023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis.
    Rabea EM; Belal MM; Hafez AH; Elbanna AH; Khalifa MA; Nourelden AZ; Mahmoud NH; Zaazouee MS
    Acta Neurol Belg; 2024 Apr; 124(2):407-417. PubMed ID: 38457005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
    Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis.
    Moccia M; Loperto I; Santoni L; Masera S; Affinito G; Carotenuto A; Lanzillo R; Triassi M; Morra VB; Palladino R
    Neurodegener Dis Manag; 2022 Jun; 12(3):109-116. PubMed ID: 35446149
    [No Abstract]   [Full Text] [Related]  

  • 11. sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients.
    Valentino P; Malucchi S; Martire S; Bava CI; Capobianco MA; Bertolotto A
    Mult Scler Relat Disord; 2022 Nov; 67():104176. PubMed ID: 36126541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study.
    Riancho J; Setien S; Sánchez de la Torre JR; Torres-Barquin M; Misiego M; Pérez JL; Castillo-Triviño T; Menéndez-García C; Delgado-Alvarado M
    Front Immunol; 2021; 12():614715. PubMed ID: 33841397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study.
    De Mercanti SF; Signori A; Cordioli C; Signoriello E; Lus G; Bonavita S; Abbadessa G; Lavorgna L; Maniscalco GT; Curti E; Lorefice L; Cocco E; Nociti V; Mirabella M; Baroncini D; Mataluni G; Landi D; Petruzzo M; Lanzillo R; Gandoglia I; Laroni A; Frangiamore R; Sartori A; Cavalla P; Costantini G; Capra R; Sormani MP; Clerico M
    J Neurol Sci; 2021 May; 424():117385. PubMed ID: 33770708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
    JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study.
    Santiago-Setien P; Barquín-Rego C; Hernández-Martínez P; Ezquerra-Marigomez M; Torres-Barquin M; Menéndez-Garcia C; Uriarte F; Jiménez-López Y; Misiego M; Sánchez de la Torre JR; Setien S; Delgado-Alvarado M; Riancho J
    Front Immunol; 2023; 14():1086028. PubMed ID: 36817456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four cases of natalizumab-related PML: a less severe course in extended interval dosing?
    Scarpazza C; De Rossi N; Tabiadon G; Turrini MV; Gerevini S; Capra R
    Neurol Sci; 2019 Oct; 40(10):2119-2124. PubMed ID: 31175467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
    Clerico M; De Mercanti SF; Signori A; Iudicello M; Cordioli C; Signoriello E; Lus G; Bonavita S; Lavorgna L; Maniscalco GT; Curti E; Lorefice L; Cocco E; Nociti V; Mirabella M; Baroncini D; Mataluni G; Landi D; Petruzzo M; Lanzillo R; Gandoglia I; Laroni A; Frangiamore R; Sartori A; Cavalla P; Costantini G; Sormani MP; Capra R
    Neurotherapeutics; 2020 Jan; 17(1):200-207. PubMed ID: 31452081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
    Mancinelli CR; Scarpazza C; Cordioli C; De Rossi N; Rasia S; Turrini MV; Capra R
    Mult Scler; 2021 Apr; 27(5):790-794. PubMed ID: 32749910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving risk-stratification of natalizumab-associated PML.
    Tugemann B; Berger JR
    Ann Clin Transl Neurol; 2021 Mar; 8(3):696-703. PubMed ID: 33539683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.